Identification of target genes and pathways regulated by miRNA-132, miRNA-182, and miRNA-124 in depression: a bioinformatics analysis
Article Sidebar
Main Article Content
Abstract
OBJECTIVE: To investigate the associations of miRNA-132, miRNA-182, and miRNA-124 with long-term depression and elucidate their target genes and translational implications utilizing miRabel, a bioinformatics tool.
METHODS: This study is a part of a randomized controlled trial conducted in Psychiatry OPD of a teaching hospital, Peshawar, Pakistan from February-2021 till December-2021. It’s a computational study using miRabel which is a miRNA target prediction instrument. This software improves bioinformatic analysis by anticipation of microRNAs targets by grading and grouping.
RESULTS: By utilizing the miRabel software, our research reveals that miRNA-132, miRNA-182, and miRNA-124 target a total of 123 genes involved in long-term depression. Out of these genes, twelve (PRKCB, PLA2G4A, PRKCG, GNAZ, GNAO1, GUCY1B3, GNAI2, PLCB3, PPP2R1A, PLCB2, GNA11, and GUCY1A2) display significant potential impact, with scores close to 1.0 (0.9). These particular genes exhibit a stronger influence compared to other target genes of miRNA-132, miRNA-182, and miRNA-124 concerning long-term depression. Our investigation also revealed that these genes target several pathways, including Beta-catenin independent WNT signaling, Corticotropin-releasing hormone relating pathway, ErbB communicating path, G protein signaling, Glutamic acid attachment, triggering of AMPA receptors, GnRH communication , Ras signaling, Serotonin and anxiety-related events, communication by WNT, Signaling by GPCR, MAPK pathway, NO/cGMP/PKG neural-preservation, Phosphodiesterases neuronal tasks, Neuroinflammation and glutamatergic signing, along with several other pathways.
CONCLUSION: miRNAs such as miRNA-132, miRNA-182, and miRNA-124, identified via comprehensive bioinformatic analysis, show potential as depression biomarkers and treatment targets. Insight into their roles and target genes within depression pathways could inspire innovative treatment strategies.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online
(e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Ferrúa CP, Giorgi R, da Rosa LC, do Amaral CC, Ghisleni GC, Pinheiro RT, et al. MicroRNAs expressed in depression and their associated pathways: A systematic review and a bioinformatics analysis. J Chem Neuroanat 2019;100:101650. https://doi.org/10.1016/j.jchemneu.2019.101650
Alvarez-Mon MA, Ortega MA, García-Montero C, Fraile-Martinez O, Monserrat J, Lahera G, et al. Exploring the role of nutraceuticals in major depressive disorder (MDD): Rationale, state of the art and future prospects. Pharmaceuticals 2021;14(8):821. https://doi.org/10.3390/ph14080821
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018;392(10159):1789-858. https://doi.org/10.1016/S0140-6736(18)32279-7
Wan Y, Liu Y, Wang X, Wu J, Liu K, Zhou J, et al. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS One 2015;10(3):e0121975. https://doi.org/10.1371/journal.pone.0121975
Lopez JP, Kos A, Turecki G. Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response. Curr Opin Psychiatry 2018;31(1):7-16. https://doi.org/10.1097/YCO.0000000000000384
Hassan M, Amir A, Shahzadi S, Kloczkowski A. Therapeutic implications of microRNAs in depressive disorders: a review. Int J Mol Sci 2022;23(21):13530. https://doi.org/10.3390/ijms232113530
Xu YY, Xia QH, Xia QR, Zhang XL, Liang J. MicroRNA-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with depression. Neuropsychiatr Dis Treat 2019;15:3583-97. https://doi.org/10.2147/NDT.S235186
Wani MY, Ganie NA, Rani S, Mehraj S, Mir MR, Baqual MF, et al. Advances and applications of Bioinformatics in various fields of life. Int J Fauna Biol Stud 2018;5(2):03-10.
Quillet A, Saad C, Ferry G, Anouar Y, Vergne N, Lecroq T, et al. Improving bioinformatics prediction of microRNA targets by ranks aggregation. Front genet 2020;10:1330. https://doi.org/10.3389/fgene.2019.01330
LITIS lab, University of Rouen Normandy, France. Accessed on: June 20, 2023. Available from URL: http://bioinfo.univ-rouen.fr/mirabel/
Lesk, Arthur M. "bioinformatics". Encyclopedia Britannica. 2023. Accessed on: June 20, 2023. Available from URL https://www.britannica.com/science/bioinformatics
National library of Medicine. PRKCB protein kinase C beta [Homo sapiens (human)] Gene ID: 5579. 2022. Accessed on: June 20, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/5579
National library of Medicine. PLA2G4A phospholipase A2 group IVA [ Homo sapiens (human)] Gene ID: 5321, updated on 21-Jun-2023. Accessed on: July 15, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/5321
National library of Medicine. PRKCG protein kinase C gamma [Homo sapiens (human)] Gene ID: 5582. 2023. Accessed on: July 25, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/5582
National library of Medicine. GNAZ G protein subunit alpha z [Homo sapiens (human)] Gene ID: 2781. 2023. Accessed on: July 21, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/2781
National library of Medicine. GNAO1 G protein subunit alpha o1 [Homo sapiens (human)] Gene ID: 2775. 2023. Accessed on: July 21, 2023. Available from URL https://www.ncbi.nlm.nih.gov/gene/2775
National library of Medicine. GNAI2 G protein subunit alpha i2 [Homo sapiens (human)] Gene ID: 2771.2023. Accessed on: July 20, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/2771
National library of Medicine. GUCY1B1 guanylate cyclase 1 soluble subunit beta 1 [Homo sapiens (human)] Gene ID: 2983. 2023. Accessed on: July 20, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/2983
National library of Medicine. PLCB2 phospholipase C beta 2 [Homo sapiens (human)] Gene ID: 5330. 2023. Accessed on: July 20, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/5330
National library of Medicine. PLCB3 phospholipase C beta 3 [Homo sapiens (human)] Gene ID: 5331. 2023. Accessed on: July 20, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/5331
National library of Medicine. PPP2R1A protein phosphatase 2 scaffold subunit Alpha [Homo sapiens (human)] Gene ID: 5518. 2023. Accessed on: July 20, 2023. Available from URL https://www.ncbi.nlm.nih.gov/gene/5518
National library of Medicine. GNA11 G protein subunit alpha 11 [Homo sapiens (human)] Gene ID: 2767. 2023. Accessed on: July 20, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/2767
National library of Medicine. GUCY1A2 guanylate cyclase 1 soluble subunit alpha 2 [Homo sapiens (human)] Gene ID: 2977. 2023. Accessed on: July 20, 2023. Available from URL: https://www.ncbi.nlm.nih.gov/gene/2977
Qian Y, Song J, Ouyang Y, Han Q, Chen W, Zhao X, et al. Advances in roles of miR-132 in the nervous system. Front Pharmacol 2017;8:770. https://doi.org/10.3389/fphar.2017.00770
Guo X, Li Z, Zhang C, Yi Z, Li H, Cao L, et al. Down-regulation of PRKCB1 expression in Han Chinese patients with subsyndromal symptomatic depression. J Psychiatr Res 2015;69:1-6. https://doi.org/10.1016/j.jpsychires.2015.07.011
Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC, et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010;67(6):550-7. https://doi.org/10.1016/j.biopsych.2009.11.005
Pandey GN, Sharma A, Rizavi HS, Ren X. Dysregulation of Protein Kinase C in Adult Depression and Suicide: Evidence from Postmortem Brain Studies. Int J Neuropsychopharmacol 2021;24(5):400-408. https://doi.org/10.1093/ijnp/pyab003
Tsolakidou A, Czibere L, Pütz B, Trümbach D, Panhuysen M, Deussing JM et al. Gene expression profiling in the stress control brain region hypothalamic paraventricular nucleus reveals a novel gene network including amyloid beta precursor protein. BMC Genomics 2010;11:546. https://doi.org/10.1186/1471-2164-11-546
Alexander JM, Pirone A, Jacob MH. Excessive β-catenin in excitatory neurons results in reduced social and increased repetitive behaviors and altered expression of multiple genes linked to human autism. Front. Synap Neurosci 2020;12:14. https://doi.org/10.3389/fnsyn.2020.00014
He JG, Zhou HY, Wang F, Chen JG. Dysfunction of Glutamatergic Synaptic Transmission in Depression: Focus on AMPA Receptor Trafficking. BP GOS 2023;3(2):187-96. https://doi.org/10.1016/j.bpsgos.2022.02.007
Dwivedi Y. MicroRNAs in depression and suicide: recent insights and future perspectives. J Affect Disord 2018;240:146-54. https://doi.org/10.1016/j.jad.2018.07.075
Zhao C, Cai H, Wang H, Ge Z. Correlation between serum renin-angiotensin system (RAS) level and depression and anxiety symptoms in patients with Parkinson's disease. Saudi J Biol Sci 2021;28(4):2146-54. https://doi.org/10.1016/j.sjbs.2021.02.029
Philips GT, Ye X, Kopec AM, Carew TJ. MAPK establishes a molecular context that defines effective training patterns for long-term memory formation. J Neurosci 2013;33(17):7565-73. https://doi.org/10.1523/JNEUROSCI.5561-12.2013
Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Progress in Prog Neuro-Psychopharmacol Biol Psychiatry 2011;35(7):1774-9. https://doi.org/10.1016/j.pnpbp.2011.05.010
Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacol 2017;42(1):193-215. https://doi.org/10.1038/npp.2016.199